ADVA
ADVA (FSE: ADV) today announced that Equinix – the world’s digital infrastructure company™ – has deployed ADVA’s FSP 3000 open optical transport technology to provide Antoni van Leeuwenhoek, one of the Netherland’s leading hospitals, with encrypted dark fiber and fully managed services. Linking the healthcare provider’s data centers and facilities, the solution enables Equinix Managed Services to deliver secure Ethernet services up to 40GbE and highly reliable, low-latency Fibre Channel storage area network (SAN) connectivity up to 32Gbit/s. With ADVA’s ConnectGuard™ optical encryption technology ensuring robust data protection, the solution gives the hospital access to bandwidth-hungry applications and allows patient and medical research information to be securely collected, managed, analyzed and shared.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005540/en/
“By harnessing ADVA FSP 3000 technology and the support of the ADVA and TrueCom teams, we’re enabling Antoni van Leeuwenhoek hospital to transform its operations. With high-capacity, low-latency connectivity to its data centers, all protected by robust encryption at the optical layer, the hospital’s medics and support staff can leverage new applications and collaborate like never before to advance cutting-edge research and enhance patient care,” said Art de Blaauw, director of technology and innovation, Managed Services Solutions at Equinix. “It’s crucial for the healthcare industry that patient data is secure. ADVA’s ConnectGuard™ solution safeguards the network stack without adding latency or affecting throughput. That means medical practitioners can access critical information at any time, which is crucial for efficient processes and patient outcomes.”
Built on ADVA’s FSP 3000 open optical transport solution, the new network is capable of secure high-capacity transmission of Ethernet services up to 40GbE. With its agile, scalable and modular design, the FSP 3000 provides a truly flexible foundation, ready to expand and evolve as the needs of the healthcare provider change. The solution enables a high-speed SAN capable of transporting 32Gbit/s Fibre Channel, ensuring rapid access to patient information. This is key for healthcare professionals dealing with huge data sets. The infrastructure is comprehensively secured at the physical layer by ADVA FSP 3000 ConnectGuard™ , which is easy to operate and highly efficient, delivering the lowest cost per bit of any network encryption solution available today. ADVA’s partner TrueCom also played a key role in this project, providing installation and support, ensuring the new infrastructure met all the end customer’s requirements.
“We’re proud that our solution is now helping another major healthcare provider optimize its operations. Protecting the integrity and privacy of patients’ sensitive data couldn’t be more critical. That’s why our security technology is so important here. It ensures valuable data remains safe at every stage of its journey, while data-intensive applications continue to run,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Approved by the German Federal Office for Information Security (BSI), our FSP 3000 ConnectGuard™ optical encryption ensures that patient records are protected by the most robust security methods available while adding virtually no delay.”
“There’s no doubt that the medical industry is at the forefront of the battle against cybercrime. Criminals see healthcare providers as treasure troves of valuable data that can easily be monetized. But thanks to our close collaboration with Equinix and ADVA, this hospital can be assured that its systems are secured,” said Dhieradj Ramanand, optical solutions sales manager at TrueCom. “With the ADVA FSP 3000 ConnectGuard™ optical security solution safeguarding data in motion right across the network, encrypted signals become worthless to a hacker. That’s why this technology is the last word in data security. It’s also the key to peace of mind for medical practitioners and their patients.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005540/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
